GLICLAGLAZE TRIO 0.3

Voglibose, metformin, and gliclazide is a combination of three oral blood-glucose-lowering medicines used for the management of type 2 diabetes mellitus in appropriate adults.

The three medicines work through different mechanisms:

• Metformin improves insulin sensitivity and reduces glucose production by the liver.

• Gliclazide is a sulfonylurea that stimulates the pancreas to release more insulin.

• Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the intestine, helping reduce the rise in blood glucose after meals.

Several products marketed in India contain this three-drug combination. For example, current Indian listings include formulations containing voglibose 0.2 mg + metformin 500 mg + gliclazide 80 mg, although strengths and release characteristics can vary by brand.

Because the exact formulation matters, consumers should check the medicine strip or prescription rather than assuming every voglibose, metformin, and gliclazide tablet contains the same doses.

Product Information 

Brand Name: GLICLAGLAZE TRIO 0.3
Composition: Voglibose 0.3 mg + Metformin 500 mg + Gliclazide 80 mg
Manufacturer/Marketer: Steris Healthcare Pvt. Ltd.
Dosage Form: Tablet
Pack Size: 15 tablets
Drug Classes: Sulfonylurea + biguanide + alpha-glucosidase inhibitor
Therapeutic Category: Anti-diabetic (oral combination therapy)
Prescription Status: Prescription required (Rx)
Primary Use: Management of type 2 diabetes mellitus in adults when blood sugar is not adequately controlled with one or two anti-diabetic agents
Target Market: India

What Is Voglibose Metformin Gliclazide Used For?

The primary use of Voglibose, Metformin, and Gliclazide is the treatment of type 2 diabetes mellitus when a healthcare professional determines that combination therapy is appropriate.

The combination may be considered when blood-glucose levels are not adequately controlled with lifestyle measures and/or fewer medicines.

The three components target different aspects of glucose regulation:

The advantage of combining medicines with different mechanisms is that they can address multiple contributors to high blood glucose. However, combination treatment also means patients need to understand the side effects and hypoglycemia risks associated with each component.

The 2026 American Diabetes Association Standards of Care emphasizes person-centered selection of glucose-lowering medicines, taking into account glycemic effectiveness, cardiovascular and kidney considerations, weight, hypoglycemia risk, adverse effects, cost, access, and patient preferences.

How Does Voglibose Metformin Gliclazide Work?

1. How does metformin work?

Metformin primarily decreases glucose production by the liver and improves the body's response to insulin.

It is widely used in type 2 diabetes. The ADA's 2026 guidance describes metformin as an effective, generally weight-neutral glucose-lowering medicine with a low risk of hypoglycemia when used alone.

Metformin can cause gastrointestinal symptoms, particularly when treatment begins. Slow dose escalation, taking it with food, and using an extended-release formulation when appropriate can improve tolerability.

2. How does gliclazide work?

Gliclazide belongs to the sulfonylurea class.

It stimulates the pancreas to produce more insulin, which lowers blood glucose.

Because it increases insulin release, gliclazide can cause hypoglycemia, especially when meals are skipped, food intake is inadequate, alcohol is consumed, or the dose is too high. NHS guidance identifies low blood sugar as an important adverse effect of gliclazide.

3. How does voglibose work?

Voglibose inhibits intestinal alpha-glucosidase enzymes involved in carbohydrate digestion.

As a result, carbohydrates are broken down and absorbed more slowly, helping reduce post-meal blood glucose spikes.

Gastrointestinal effects such as flatulence, bloating, abdominal discomfort, and diarrhea are characteristic of alpha-glucosidase inhibition because undigested carbohydrates remain in the intestine longer.

Key Benefits of Voglibose, Metformin, and Gliclazide

1. Multiple mechanisms for blood-glucose control: One of the main advantages of the combination is that each component works differently. Metformin primarily addresses excessive hepatic glucose production and insulin resistance, gliclazide increases insulin secretion, and voglibose targets carbohydrate absorption after meals.This complementary approach can help some people achieve better glycemic control than a single medicine alone.

2. Helps control blood sugar in type 2 diabetes: The combination is specifically used to help lower elevated blood glucose in adults with type 2 diabetes. However, the goal is not simply to reduce a single glucose reading. Long-term diabetes management generally involves monitoring measures such as HbA1c, blood glucose patterns, body weight, kidney function, and cardiovascular risk.

3. Can target post-meal glucose elevations: Voglibose is particularly relevant to glucose rises after eating. This can be useful when post-meal blood glucose contributes significantly to overall glycemic exposure.

4. Metformin generally has a low hypoglycemia risk when used alone: Metformin itself does not typically cause hypoglycemia when used as monotherapy. However, when it is combined with an insulin-releasing medicine such as gliclazide, the overall treatment regimen can cause low blood sugar. The ADA specifically identifies sulfonylureas as medicines with hypoglycemia risk.

5. Oral combination therapy: For eligible patients, an oral combination can simplify treatment compared with taking multiple separate tablets, although whether a fixed-dose combination is appropriate depends on the patient's prescribed doses and clinical situation.

Side Effects 

Because this medicine contains three active ingredients, side effects can come from any component.

Commonly reported problems can include:

• Nausea

• Abdominal discomfort

• Diarrhea

• Constipation

• Vomiting

• Bloating

• Gas or flatulence

• Loss of appetite

• Indigestion

• Low blood sugar

Indian medicine information for this combination lists nausea, hypoglycemia, abdominal pain, and constipation among possible common adverse effects.

Voglibose is particularly associated with gastrointestinal symptoms such as flatulence, bloating, abdominal discomfort, diarrhea, and nausea.

Metformin commonly causes gastrointestinal intolerance, including bloating, abdominal discomfort, and diarrhea.

Frequently Asked Questions 

1. What are Voglibose, Metformin, and Gliclazide used for?

Voglibose, metformin, and gliclazide is an oral combination medicine used to help control type 2 diabetes mellitus in adults when combination treatment is prescribed.

2. What are the three medicines in Voglibose, Metformin, and Gliclazide?

The combination contains voglibose, metformin, and gliclazide. The exact strength varies by product; one commonly listed Indian formulation contains 0.2 mg voglibose, 500 mg metformin, and 80 mg gliclazide.

3. How do voglibose, metformin, and gliclazide work?

Metformin reduces excessive glucose production by the liver and improves insulin sensitivity, gliclazide increases insulin release from the pancreas, and voglibose slows carbohydrate digestion and absorption.

4. Do voglibose, metformin, and gliclazide lower blood sugar?

Yes. The three medicines are glucose-lowering agents used together to improve blood-glucose control in appropriate people with type 2 diabetes.

5. Can voglibose, metformin, and gliclazide cause low blood sugar?

Yes. Gliclazide can cause hypoglycemia, particularly if meals are skipped, food intake is inadequate, alcohol is consumed, or the dose is excessive.

6. What are the common side effects of voglibose, metformin, and gliclazide?

Possible side effects include nausea, abdominal discomfort, diarrhea, constipation, bloating, gas, vomiting, and low blood sugar.

7. Does Voglibose cause gas?

Yes. Flatulence, bloating, abdominal discomfort, and diarrhea are recognized effects associated with voglibose and other alpha-glucosidase inhibitors.

8. Can I take voglibose, metformin, and gliclazide without food?

Do not change the prescribed timing. Because gliclazide and voglibose are related to meals, many formulations are taken with food. Follow the specific instructions supplied with your product and prescription.

9. Can I take this medicine if I skip breakfast?

Do not routinely skip meals while taking a medicine containing gliclazide because irregular or missed meals can increase the risk of hypoglycemia.

10. Is Voglibose, Metformin, or Gliclazide safe for kidney disease?

It depends on the severity of kidney impairment and the exact clinical situation. Metformin requires particular attention to eGFR, and the ADA states it is contraindicated below an eGFR of 30 mL/min/1.73 m².